These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 22410751)

  • 1. Extramedullary disease in plasma cell myeloma: the iceberg phenomenon.
    Wirk B; Wingard JR; Moreb JS
    Bone Marrow Transplant; 2013 Jan; 48(1):10-8. PubMed ID: 22410751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach.
    Bladé J; Fernández de Larrea C; Rosiñol L; Cibeira MT; Jiménez R; Powles R
    J Clin Oncol; 2011 Oct; 29(28):3805-12. PubMed ID: 21900099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome.
    Zeiser R; Deschler B; Bertz H; Finke J; Engelhardt M
    Bone Marrow Transplant; 2004 Dec; 34(12):1057-65. PubMed ID: 15516937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal failure in multiple myeloma: a medical emergency.
    Wirk B
    Bone Marrow Transplant; 2011 Jun; 46(6):771-83. PubMed ID: 21339749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome.
    Minnema MC; van de Donk NW; Zweegman S; Hegenbart U; Schonland S; Raymakers R; Zijlmans JM; Kersten MJ; Bos GM; Lokhorst HM
    Bone Marrow Transplant; 2008 May; 41(9):779-84. PubMed ID: 18195681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
    El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
    Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
    Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
    Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma.
    Terpos E; Rezvani K; Basu S; Milne AE; Rose PE; Scott GL; Rahemtulla A; Samson D; Apperley JF
    Eur J Haematol; 2005 Nov; 75(5):376-83. PubMed ID: 16191086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical analysis of multiple myeloma with extramedullary plasmacytomas].
    Li X; Sun WJ; Chen SL; Zhong YP; An N; Hu Y; Zhang JJ; Liu XH
    Zhonghua Yi Xue Za Zhi; 2012 Mar; 92(12):838-41. PubMed ID: 22781459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Multiple myeloma relapsed or progressed as plasmacytoma after allogeneic reduced-intensity stem cell transplantation: report of three cases].
    Sugimoto Y; Nishii K; Miyata E; Fujieda A; Yamaguchi M; Masuya M; Katayama N
    Rinsho Ketsueki; 2009 Apr; 50(4):289-94. PubMed ID: 19404022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.
    Beksac M; Seval GC; Kanellias N; Coriu D; Rosiñol L; Ozet G; Goranova-Marinova V; Unal A; Bila J; Ozsan H; Ivanaj A; Balić LI; Kastritis E; Bladé J; Dimopoulos MA
    Haematologica; 2020 Jan; 105(1):201-208. PubMed ID: 31278209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Localized extramedullary relapse after autologous hematopoietic stem cell transplantation in multiple myeloma.
    Erkus M; Bolaman Z; Meteoglu I; Kadikoylu G
    Saudi Med J; 2005 Jun; 26(6):989-91. PubMed ID: 15983690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation: better prognosis than systemic relapse.
    Solh M; DeFor TE; Weisdorf DJ; Kaufman DS
    Biol Blood Marrow Transplant; 2012 Jan; 18(1):106-12. PubMed ID: 21703975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late relapse of a light-chain myeloma as extramedullary plasmacytoma of the thyroid gland after second allogeneic stem-cell transplantation.
    Ozdemir E; Bayraktar M; Sökmensüer C; Kir KM; Kansu E
    Clin Transplant; 2009; 23(6):981-4. PubMed ID: 19689453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of central nervous system myeloma in the era of novel agents.
    Gangatharan SA; Carney DA; Prince HM; Wolf MM; Januszewicz EH; Ritchie DS; Harrison SJ
    Hematol Oncol; 2012 Dec; 30(4):170-4. PubMed ID: 22144117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.
    Farina L; Bruno B; Patriarca F; Spina F; Sorasio R; Morelli M; Fanin R; Boccadoro M; Corradini P
    Leukemia; 2009 Jun; 23(6):1131-8. PubMed ID: 19194465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal allografts in plasma cell myeloma hematopoietic cell graft recipients: on the verge of an explosion?
    Nayak L; Lazarus HM
    Bone Marrow Transplant; 2013 Mar; 48(3):338-45. PubMed ID: 22732698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma.
    Arora M; McGlave PB; Burns LJ; Miller JS; Barke JN; Defor TE; Weisdorf DJ
    Bone Marrow Transplant; 2005 Jun; 35(12):1133-40. PubMed ID: 15834435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.